Header Pix Nebulizer

Videos about our Nebulizer

Please accept marketing-cookies to watch this video.

The direct comparison shows it clearly: Our QuattroJet® (left) ensures an even and efficient distribution of aerosols, while the competitor product (right) has an uneven and less effective release.

✅ Maximum area coverage
✅ Efficient and uniform wetting
✅ Optimum performance for demanding applications

With QuattroJet® you can be assured of the latest technology for the best results.

Nebulizer

The Golden Standard since 2012

mehr erfahren

QuattroJet®

4-Nozzle-Technology 

mehr erfahren

Minijet

for use with a small 5mm trocar

mehr erfahren

History

2009
The beginning of a new era

REGER develops the first nebulizer for the PIPAC, which was researched by Prof. Marc Reymond. This development marks the start of a new dimension in the precise nebulization of chemotherapeutic agents.

2012
Groundbreaking work in PIPAC therapy

The innovative nebulizers from REGER (formerly MIP®) are used for the first time in the pioneering PIPAC therapy. They are setting new standards in the targeted and efficient application of chemotherapeutic medication in the abdomen and are quickly gaining the trust of leading oncologists.

2015
Growth through exclusive sales

The aerosol dispensers manufactured by REGER are distributed exclusively by Capnomed, which led to the technology gaining international recognition. During this time, PIPAC therapy becomes increasingly established in medical facilities worldwide, and REGER plays a key role in this development.

2022
Direct sales for more customer proximity

After seven years of exclusive distribution, REGER is taking over direct distribution of its own products. This allowes a more direct exchange with users, a faster market launch of new technologies and an even more targeted further development of products based on feedback from medical professionals.

2023
Introduction of the QuattroJet: A new dimension of nebulization

With the market launch of the QuattroJet, an advanced nebulizer with four nozzles, REGER is setting new standards in the application of chemotherapeutic medication in the abdominal cavity. This innovation ensures an even more homogeneous distribution of the aerosol and significantly improves the effectiveness of PIPAC therapy.

2023
510(k) Clearance for the US

REGER receives 510(k) clearance for the US market.

2025
MDR Class IIb certification for the highest safety standards

REGER's Nebulizers achieve MDR Class IIb certification and are therefore approved not only for the nebulization of fluids but also for the nebulization of chemotherapeutic agents for PIPAC.

Studies with REGER products

The following section contains the most significant studies that have explicitly used REGER products.

Publications with REGER products